Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia.

Black MD, Selk DE, Hitchcock JM, Wettstein JG, Sorensen SM.

Neuropharmacology. 1999 Sep;38(9):1299-306.

PMID:
10471083
2.

Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease.

Smith CP, Bores GM, Petko W, Li M, Selk DE, Rush DK, Camacho F, Winslow JT, Fishkin R, Cunningham DM, Brooks KM, Roehr J, Hartman HB, Davis L, Vargas HM.

J Pharmacol Exp Ther. 1997 Feb;280(2):710-20.

PMID:
9023283
3.

Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.

Bores GM, Huger FP, Petko W, Mutlib AE, Camacho F, Rush DK, Selk DE, Wolf V, Kosley RW Jr, Davis L, Vargas HM.

J Pharmacol Exp Ther. 1996 May;277(2):728-38.

PMID:
8627552
4.

Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquinolinones as potential agents for the treatment of Alzheimer's disease.

Fink DM, Bores GM, Effland RC, Huger FP, Kurys BE, Rush DK, Selk DE.

J Med Chem. 1995 Sep 1;38(18):3645-51.

PMID:
7658452

Supplemental Content

Support Center